Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Remitly Global Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $279.68 (market cap $39.89B), while Remitly Global Inc trades at $23.99 (market cap $5.01B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 8× Remitly Global Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | RELY | |
|---|---|---|
Market Cap | $39.89B | $5.01B |
Sector | Health | Technology |
52-Week High | $491.22 | $24.28 |
52-Week Low | $278.09 | $12.20 |
Enterprise Value | $38.15B | $4.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
RELY trades at $23.77, up 0.89% today, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q1 2026 EPS of $0.23, beating expectations, and raised full-year guidance to $1.96–$1.975 billion revenue. Recent news highlights a UAE license and market share gains.
Outlook is positive with 92% analyst buy ratings and a $26.75 consensus target, but high P/E of 49.52 and competitive pressures in remittance pose risks. Profitability has turned positive, with net income reaching $67.93M in 2025 after prior losses, signaling a sustainable growth trajectory if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
